[(1R,4S)-3-(5-amino-3-methyl-1,3,4,6,8-pentaazaacenaphthylen-1(3H)-yl)cyclopentyl]methanol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: [(1R,4S)-3-(5-amino-3-methyl-1,3,4,6,8-pentaazaacenaphthylen-1(3H)-yl)cyclopentyl]methanol
• 英文别名: carbocyclic D-2',3'-dideoxytriciribine；Cyclopentanemethanol, 3-(3-amino-5-methyl-1,4,5,6,8-pentaazaacenaphthylen-1(5H)-yl)-, (1R,3S)-；[(1R,3S)-3-(5-amino-7-methyl-2,6,7,9,11-pentazatricyclo[6.3.1.04,12]dodeca-1(12),3,5,8,10-pentaen-2-yl)cyclopentyl]methanol
• 化学式: C₁₄H₁₈N₆O
• 分子量: 286.337
• InChiKey: FHXJFXHYIPXGED-BDAKNGLRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  92.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  [(1R,4S)-3-(4-chloro-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentyl]methyl acetate 在 氨 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 52.0h， 生成 [(1R,4S)-3-(5-amino-3-methyl-1,3,4,6,8-pentaazaacenaphthylen-1(3H)-yl)cyclopentyl]methanol
  参考文献：
  名称：

  合成2'，3'-二脱氧桑奇霉素，2'，3'-二脱氧代代霉素和2'，3'-二脱氧三iri啶的碳环类似物。

  摘要：

  描述了新的2'，3'-双脱氧桑奇霉素，2'，3'-双脱氧代托卡霉素和2'，3'-双脱氧三丁胺的碳环类似物的合成和抗病毒活性。关键中间体，碳环4-氯-5-碘吡咯并嘧啶。通过使用I2和CF3COOAg的新型碘化方法，以高收率合成了SnO2。然后使该碳环的4-氯-5-碘吡咯并并嘧啶精制所需的4，5-二取代的碳环核苷。

  DOI：

  10.1081/ncn-100107193

文献信息

• Methods of treating breast cancer that overexpress AKT kinase
  申请人：University of South Florida

  公开号：US10744148B2

  公开（公告）日：2020-08-18

  This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.

  本申请涉及包括曲克瑞滨化合物和表皮生长因子受体抑制剂化合物，特别是厄洛替尼类化合物的组合疗法，以及毒性降低的组合物，用于治疗和预防肿瘤、癌症和其他与细胞异常增殖有关的疾病。
• Compositions and methods for preserving red blood cells and platelets
  申请人：RythRx Therapeutics, LLC

  公开号：US10779529B2

  公开（公告）日：2020-09-22

  Blood and platelet storage and rejuvenating compositions that include triciribine, triciribine metabolites, triciribine analogs, and mixtures of the same are disclosed. Such compositions can be useful in methods for treating (e.g., storing and rejuvenating) red blood cells and platelets.

  本发明公开了包括曲克瑞滨、曲克瑞滨代谢物、曲克瑞滨类似物及其混合物的血液和血小板储存与再生组合物。此类组合物可用于治疗（如储存和恢复活力）红细胞和血小板的方法。
• Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
  申请人：University of South Florida

  公开号：US10780104B2

  公开（公告）日：2020-09-22

  This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.

  本申请涉及包括曲克瑞滨化合物和表皮生长因子受体抑制剂化合物，特别是厄洛替尼类化合物的组合疗法，以及毒性降低的组合物，用于治疗和预防肿瘤、癌症和其他与细胞异常增殖有关的疾病。
• COMPOSITIONS INCLUDING TRICIRIBINE AND TRASTUZUMAB AND METHODS OF USE THEREOF
  申请人：Cheng Jin Q.

  公开号：US20100028339A1

  公开（公告）日：2010-02-04

  This application relates to combination therapies including triciribine and related compounds and trastuzumab or a salt thereof and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
• EFFECTIVE TREATMENT OF ESOPHOGEAL ADENOCARCINOMA USING TRICIRIBINE AND RELATED COMPOUNDS
  申请人：CHENG Jin Q.

  公开号：US20120202765A1

  公开（公告）日：2012-08-09

  The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat esophogeal adenocarcinoma by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug.